Event Details

Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics

Monday, April 08, 2019 at 8:30 am EDT

Webcast Presentation